Louis Bock - Heat Biologics Independent Director
Director
Mr. Louis C. Bock was appointed as Independent Director of the Company. Mr. Bock joined Scale Venture Partners in September 1997 from Gilead Sciences, Inc., a biopharmaceutical company where he worked from September 1989 to September 1997. Prior to Gilead, he was a research associate at Genentech, Inc. from November 1987 to September 1989. He currently serves as a director of the following publicly traded companies Orexigen Therapeutics, Inc., for which he also serves as a member of the Audit and Nominating and Governance committees, and Zogenix, Inc., for which he also serves as a member of the Audit, Compensation and Nominating and Governance committees. In addition, Mr. Bock serves on the board of directors of the following privatelyheld companies Molecular Templates, CardioKinetix and Powervision and also serves on the board of directors of Arizona Technology Enterprises, LLC, a nonprofit organization. Mr. Bock is responsible for Scale Venture Partners investment in Seattle Genetics, Inc. In the past five years, Mr. Bock has also served as a member of the boards of directors of the following publicly traded companies diaDexus Inc and Horizon Pharma, Inc since 2013.
| Age | 51 |
| Tenure | 11 years |
| Professional Marks | MBA |
| Phone | 919 240 7133 |
| Web | https://www.heatbio.com |
Heat Biologics Management Efficiency
The company has return on total asset (ROA) of (17.1) % which means that it has lost $17.1 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (31.12) %, meaning that it created substantial loss on money invested by shareholders. Heat Biologics' management efficiency ratios could be used to measure how well Heat Biologics manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 1.93 M in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Heat Biologics has a current ratio of 20.62, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Heat Biologics until it has trouble settling it off, either with new capital or with free cash flow. So, Heat Biologics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Heat Biologics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Heat to invest in growth at high rates of return. When we think about Heat Biologics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Andrew Quinn | Barrick Gold Corp | 66 | |
| Anthony Munk | Barrick Gold Corp | 57 | |
| Pablo Marcet | Barrick Gold Corp | 53 | |
| Cathie Markus | Harmony Gold Mining | 56 | |
| Jemaluddin Kassum | Barrick Gold Corp | 68 | |
| Daniel Lougher | Perseus Mining Limited | 53 | |
| Andre Wilkens | Harmony Gold Mining | 68 | |
| James Jones | Cumberland Pharmaceuticals | 67 | |
| Gustavo Cisneros | Barrick Gold Corp | 74 | |
| Mashego Mashego | Harmony Gold Mining | 45 | |
| Steven Shapiro | Barrick Gold Corp | 65 | |
| Robert Burke | Dyadic International | N/A | |
| Michael Tarnok | Dyadic International | 59 | |
| Seth Herbst | Dyadic International | N/A | |
| Graham Clow | Barrick Gold Corp | 66 | |
| Joey Jacobs | Cumberland Pharmaceuticals | 63 | |
| Brett Harvey | Barrick Gold Corp | 67 | |
| Given Sibiya | Harmony Gold Mining | N/A | |
| Mavuso Msimang | Harmony Gold Mining | 75 | |
| Harry Mashego | Harmony Gold Mining | 55 | |
| Graham MSc | Abcellera BiologicsInc | N/A | |
Management Performance
| Return On Equity | -31.12 | |||
| Return On Asset | -17.1 |
Heat Biologics Leadership Team
Elected by the shareholders, the Heat Biologics' board of directors comprises two types of representatives: Heat Biologics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Heat. The board's role is to monitor Heat Biologics' management team and ensure that shareholders' interests are well served. Heat Biologics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Heat Biologics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Edward Smith, Independent Director | ||
| Timothy Creech, CFO | ||
| Melissa Price, VP of Product Devel. | ||
| John Monahan, Independent Director | ||
| Louis Bock, Independent Director | ||
| Taylor Schreiber, Vice President - Research and Development | ||
| Ann Rosar, Vice President - Finance, Corporate Secretary | ||
| Paul Belsky, Independent Director | ||
| Mark Weinberg, Executive Vice President - Clinical Development | ||
| Anil Goyal, VP of Bus. Devel. | ||
| Jeff Hutchins, Chief Scientific Officer, Senior Vice President - Pre-Clinical Development | ||
| Michael Kharitonov, Independent Director | ||
| Robert Jakobs, Controller | ||
| John Prendergast, Director | ||
| Melissa Conger, IR Contact Officer | ||
| Jeffrey Wolf, Chairman of the Board, CEO | ||
| Durham NC, IR Contact Officer |
Heat Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Heat Biologics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -31.12 | |||
| Return On Asset | -17.1 | |||
| Current Valuation | (34.74 M) | |||
| Shares Outstanding | 25.4 M | |||
| Shares Owned By Insiders | 5.20 % | |||
| Shares Owned By Institutions | 10.77 % | |||
| Number Of Shares Shorted | 1.17 M | |||
| Price To Earning | (1.29) X | |||
| Price To Book | 0.48 X | |||
| Price To Sales | 28.62 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Heat Biologics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Heat Biologics' short interest history, or implied volatility extrapolated from Heat Biologics options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Heat Biologics information on this page should be used as a complementary analysis to other Heat Biologics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Other Consideration for investing in Heat Stock
If you are still planning to invest in Heat Biologics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Heat Biologics' history and understand the potential risks before investing.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |